Alpha Emitter Radium 223 in High-Risk Osteosarcoma
Authors:
Open Access
- 1 May 2015
- journal article
- observation
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 1 (2) , 253-255
Abstract
Osteosarcoma is the most common primary malignant condition of the bone in children, adolescents, and young adults. We have reached a therapeutic plateau with sKeywords
This publication has 6 references indexed in Scilit:
- Bone-Seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-2232014
- Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 2014
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphomaLeukemia & Lymphoma, 2007
- Implications of the blood–brain barrier in primary central nervous system lymphomaNeurosurgical Focus, 2006
- High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?Clinical Cancer Research, 2006